| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION. LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | Orbicular Pharmaceutical Technologies Private Limited | Gland Pharma Limited | 20260416 | 2 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION. LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | Hikma Pharmaceuticals USA Inc. | 20260330 | 6 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION. LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | Orbicular Pharmaceutical Technologies Private Limited | Gland Pharma Limited | 20260312 | 1 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION. LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | Teva Pharmaceuticals, Inc. | 20260227 | 4 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION. LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | Cipla USA Inc. | GLAND PHARMA LIMITED | 20260225 | 3 |
| These highlights do not include all the information needed to use SAXENDA ® safely and effectively. See full prescribing information for SAXENDA. SAXENDA (liraglutide) injection, for subcutaneous use Initial U.S. Approval: 2010 | Novo Nordisk | 20260225 | 21 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION. LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | NorthStar Rx LLC | Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. | 20260216 | 2 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION . LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | Teva Pharmaceuticals USA, Inc. | 20260130 | 3 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION. LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | Meitheal Pharmaceuticals Inc. | Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. | 20260130 | 8 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION. LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | Cipla USA Inc. | GLAND PHARMA LIMITED | 20260112 | 2 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION. LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | Lupin Pharmaceuticals, Inc. | LUPIN LIMITED | 20251113 | 10 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION. LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | Biocon Pharma Inc. | Biocon Pharma Limited | Biocon Biologics Limited | 20251016 | 8 |
| These highlights do not include all the information needed to use VICTOZA ® safely and effectively. See full prescribing information for VICTOZA. VICTOZA (liraglutide) injection, for subcutaneous use Initial U.S. Approval: 2010 | Novo Nordisk | 20251014 | 31 |
| These highlights do not include all the information needed to use XULTOPHY 100/3.6 safely and effectively. See full prescribing information for XULTOPHY 100/3.6 . XULTOPHY ® 100/3.6 (insulin degludec and liraglutide) injection, for subcutaneous use Initial U.S. Approval: 2016 | Novo Nordisk | 20251014 | 14 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION. LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | Biocon Pharma Inc. | Biocon Pharma Limited | Biocon Biologics Limited | 20251010 | 12 |
| These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION . LIRAGLUTIDE injection, for subcutaneous use Initial U.S. Approval: 2010 | A-S Medication Solutions | 20250130 | 1 |
| 1a372465-d56b-2b80-e063-6394a90a3304 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | 20241203 | 4 |
| 1a36f43f-d734-97cc-e063-6294a90ae0da | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | 20241202 | 3 |
| 1a36b801-41e2-2eed-e063-6294a90a6f27 | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | 20240605 | 1 |
| These highlights do not include all the information needed to use SAXENDA ® safely and effectively. See full prescribing information for SAXENDA. SAXENDA (liraglutide) injection, for subcutaneous use Initial U.S. Approval: 2010 | A-S Medication Solutions | 20240126 | 6 |
| These highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA. VICTOZA ® (liraglutide) injection, for subcutaneous use Initial U.S. Approval: 2010 | A-S Medication Solutions | 20230206 | 9 |
| These highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA. VICTOZA ® (liraglutide) injection, for subcutaneous use Initial U.S. Approval: 2010 | A-S Medication Solutions | 20230206 | 5 |